Key facts
- It has raised $47.0M; the latest was Later Stage VC ($42.4M) in Dec 2024.
- Notable investors include Bpifrance, Sofilaro, SPRIM Global Investments, Capitole Angels, Aris (Other Financial Services) — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Cilcare
- ·The full record, as it builds
Funding rounds
No funding rounds for Cilcare are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cilcare
Operator of a biotechnology company intended to deliver treatment of hearing disorders. The company's technology utilizes auditory sciences for the early definition, detection, and treatment of synaptopathy in neurocognitive and inflammatory diseases, enabling doctors to provide effective treatments to patients suffering from ear diseases.
- Sector
- Healthcare
- HQ
- Montpellier, France
- Founded
- 2014
- Employees
- 59
- Website
- cilcare.com/
- Ownership
- Privately Held (backing)
Cilcare doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cilcare shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cilcare in its N-PORT filings yet. We sweep new filings monthly.